Darifen ER Tablet 7.5 mg contains Darifenacin, a selective muscarinic M3 receptor antagonist used in the management of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence. The extended-release (ER) formulation allows once-daily dosing, providing sustained therapeutic effects, better compliance, and consistent symptom control throughout the day. Darifenacin works by reducing involuntary bladder muscle contractions, improving bladder capacity, and enhancing quality of life in patients suffering from OAB.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active Ingredient: Darifenacin 7.5 mg

• Dosage Form: Extended-release oral tablet

• Route of Administration: Oral

Mechanism of Action

Darifenacin is a selective M3 muscarinic receptor antagonist that targets receptors in the bladder detrusor muscle:

• Blocks M3 receptors, which are responsible for bladder muscle contraction

• Reduces involuntary bladder contractions, increasing bladder capacity

• Decreases urinary urgency, frequency, and incontinence episodes

• Minimizes effects on other muscarinic receptors, reducing side effects such as dry mouth, constipation, or blurred vision compared to non-selective antimuscarinics

By selectively targeting M3 receptors, Darifen ER provides effective symptom relief while maintaining a favorable safety profile.

Indications

Darifen ER Tablet 7.5 mg is indicated for:

• Management of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence

• Patients experiencing urinary urge incontinence that affects daily activities or quality of life

• Long-term treatment of OAB where non-pharmacological interventions (like bladder training) are insufficient

Dosage and Administration

• The recommended starting dose is 7.5 mg once daily, taken orally with or without food

• Tablets should be swallowed whole; do not crush, chew, or split the ER tablets

• Dose may be increased to 15 mg once daily based on clinical response and tolerability

• Adequate hydration is recommended to prevent urinary retention or constipation

• Regular monitoring may be necessary in elderly patients or those with pre-existing renal or hepatic conditions

Contraindications

Darifen ER Tablet 7.5 mg should not be used in:

• Patients with hypersensitivity to Darifenacin or other antimuscarinics

• Urinary retention or gastric retention

• Uncontrolled narrow-angle glaucoma

• Severe hepatic impairment

Precautions and Warnings

• Use with caution in patients with impaired renal or hepatic function

• May cause dry mouth, constipation, or blurred vision; maintain adequate hydration and fiber intake

• Elderly patients may be more susceptible to anticholinergic side effects

• Avoid concomitant use with strong CYP3A4 inhibitors, which may increase Darifenacin levels

• Discontinue if severe urinary retention or gastrointestinal obstruction occurs

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Darifen ER Tablet 7.5 mg is generally well tolerated. Common side effects include:

• Dry mouth

• Constipation

• Blurred vision

• Headache or dizziness

• Rare effects: urinary retention, gastrointestinal discomfort, or allergic reactions

Storage

Store below 30°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Conclusion

Darifen ER Tablet 7.5 mg is an effective and convenient option for managing overactive bladder symptoms. Its selective action on M3 receptors provides targeted relief from urgency, frequency, and urge incontinence with minimal systemic side effects. The extended-release formulation ensures once-daily dosing, improving adherence and enhancing quality of life for patients with OAB.